Medtronic's Evolut Pro TAVR valve treating aortic stenosis

Medtronic TAVR valves at heart of key studies presented during PCR London Valves 2024

One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules

Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Gilbert H. Tang, MD, professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine and surgical director of the Structural Heart Program at the Mount Sinai Health System, explains how to overcome the limited imaging windows of the tricupid valve using a TEE and intracardiac echo (ICE) at TCT 2024.

How to overcome imaging challenges during tricuspid valve procedures

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. 

PCI

Contrast injections during angiography, PCI unlikely to cause coronary injuries

The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. 

Charles E. Mullins, MD, a U.S. Army veteran known as a legend of interventional pediatric cardiology, died Nov. 17. He was 92 years old.

Charles E. Mullins remembered as a pioneer of interventional pediatric cardiology

Charles E. Mullins, MD, a U.S. Army veteran who went on to practice medicine for five decades, died at the age of 92. SCAI shared a loving tribute to Mullins, calling him the "father of modern interventional pediatric cardiology."

Sapien 3 Ultra Resilia TAVR valves

Newest TAVR valve from Edwards linked to better 1-year outcomes than its predecessors

The Sapien 3 Ultra Resilia TAVR valve from Edwards Lifesciences is associated with a significantly higher survival rate after one year than the company's previous balloon-expandable valves. Researchers identified other key benefits as well, sharing their findings in JACC: Cardiovascular Interventions.

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.